PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger P... ( ANNAPOLIS Md. Oct. 27 /- PharmAth...)

PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)

Date:10/27/2008

ANNAPOLIS, Md., Oct. 27 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE ALTERNEXT US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a U.S. Phase I clinical trial evaluating Protexia(R) for safety and tolerability in humans. Protexia(R), which is produced in the milk of transgenic goats, is a recombinant version of human butyrylcholinesterase (BChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents.

The randomized, placebo-controlled, third-party double-blind, dose escalating Phase I clinical trial will study Protexia(R) administered intramuscularly at one and two time points in healthy human volunteers. Approximately 32 subjects will participate in the study, comprised of healthy male and female volunteers between the ages of 18 and 55 years who are willing to give informed consent and are in general good health.

Under the study protocol, either Protexia(R) or a saline control will be administered in escalating doses to five groups of volunteers. Safety data through 14 days post-dosing will be evaluated prior to escalation to a higher dose. Subjects in four of the groups (comprised of six subjects each) will receive a single dose of Protexia(R) and participate in the trial for two and a half months. One group of eight subjects will receive a second dose of Protexia(R) approximately 72 days following the first dose and will participate in the study for approximately five months.

The primary endpoint of the study is an evaluation of the safety, tolerability, pharmacokinetics and immunogenicity of escalating single doses of Protexia(R) given intramuscularly in healthy human volunteers. The secondary endpoint will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of a second dose of Protexia(R) in one dose cohort.

"The initiation of pati
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
4. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
5. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
6. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
9. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
10. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
11. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

Post Your Comments:

(Date:5/22/2013)... and VANCOUVER, British Columbia , May ... ), a leader in the development of novel therapeutics to ... four trials of its investigational compounds, custirsen and OGX-427, will ... th Annual Meeting of the American Society of Clinical ... May 31 – June 4. Despite the ...

(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...

(Date:5/21/2013)... N.Y., May 21, 2013 Lakeland Industries, Inc. ... manufacturer of industrial protective clothing for industry, municipalities, ... and local levels, today announced that the Company ... a Senior Credit Facility subject to certain terms ... this financing. However, no assurances can be given ...

[0] OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [0] Concord Medical Reports First Quarter 2013 Financial Results [0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results

... N.J., Nov. 9 Unwavering from its pursuit of ... climate, Lutronic, Inc., a leading developer of high quality ... fractional CO2 device priced at under $50,000. , ... to Lutronic,s fractional technology including scanning and stamping operation ...

... (NYSE Amex: KAD ), a leading provider of ... brand, has appointed Stephen Goldsmith to its Board of ... his resignation from the Board. , ... is the Daniel Paul Professor of Government and Director ...

Cached Medicine Technology:Lutronic(R) Unleashes the New MOSAIC CO2 2 Arcadia Resources Names Stephen Goldsmith to Board of Directors 2 Arcadia Resources Names Stephen Goldsmith to Board of Directors 3

Lutronic(R) Unleashes the New MOSAIC CO2 Arcadia Resources Names Stephen Goldsmith to Board of Directors

(Date:5/21/2013)... 21, 2013 Patients of Dr. Michael Shenk ... lost teeth due to gum disease and would like permanent ... disease treatment with laser gum surgery. Gum disease ... highest success rate out of all tooth replacement options. ... relatively new procedure cleared by the Food and Drug Administration ...

(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...

(Date:5/21/2013)... SOURCE XT one of the largest, post-approval transcatheter ... at EuroPCR 2013 show good clinical outcomes in routine ... all access approaches, valve sizes and delivery systems. , ... enrolled patients (mean age 81.5 years) undergoing TAVI with ... 17 countries between July 2010 and October 2011. Access ...

(Date:5/21/2013)... The In View series , a ... channels across the country, announces it has posted a ... producers of the series proudly bring audiences across the ... manufacturing industry, health-related companies, medical facilities and more. The ... in all parts of the United States, Canada and ...

(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... relationships. With the help of Texas Counseling’s Sexuality ... of communication, and the development of healthier habits ... group workshops available for both couples and individuals ... couples enhance their relationships and learn skills to ...

Breaking Medicine News(10 mins):Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2 Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2 Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2 Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2

[0] Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA [0] ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services [0] Post-approval TAVI registry shows high rates of device success at 1 year [0] In View hosted by Larry King Announces New Videos on its YouTube Channel [0] Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships

... Human Vaccine Institute today announced a collaboration and ... enable the rapid development of a vaccine and ... threat such as pandemic influenza. The team, composed ... of the National Institute of Allergy and Infectious ...

... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) -- While ... the past few decades, this tragic outcome is still a reality ... a series of studies published online April 14 in The ... in the United States may be obesity, which can raise the ...

... of minor illnesses of astronauts in space may require special ... the space environment. That,s according to Dr. Putcha and ... published online in The AAPS Journal suggest that ... shorter shelf-life than they do on Earth. Pharmaceuticals used ...

... The judgments we make about the intimacy of ... brain chemical serotonin, reports a new study published in ... of serotonin activity had been lowered, rated couples in ... volunteers with normal serotonin activity. The approach involved giving ...

... (HealthDay News) -- Home safety devices greatly reduce the ... a new study. Researchers at Cincinnati Children,s Hospital ... newborns. One set of families had properly installed and ... cabinet locks, electrical outlet covers, smoke alarms, carbon monoxide ...

... By Amanda Gardner HealthDay Reporter , ... highlight the complexities hospitals face in controlling and containing ... to many antibiotics. While one study showed that ... Staphylococcus aureus (MRSA), the other found no ...

Cached Medicine News:Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2 Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3 Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 2 Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 3 Health News:Drug potency -- what happens in space? 2 Health News:Serotonin: A critical chemical for human intimacy and romance 2 Health News:With Safety Devices in Place, Kids' Injuries Decline: Study 2 Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 2 Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 3

Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies Drug potency -- what happens in space?Serotonin: A critical chemical for human intimacy and romance With Safety Devices in Place, Kids' Injuries Decline: Study Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals

5 mm concave jaws, cross action....

... inserter is the first of its kind. ... through a minimal incision. The special direct-acting ... bag with complete control and predictability. The ... easy around-the-clock, and the instrument has a ...

... SI-30 and SI-40 foldable lenses through incisions as ... clear corneal and corneal scleral tunnels. The inserter ... rounded blades for a secure grasp of a ... a .15 millimeter notch which may be used ...

KR-8000 Supra is capable of obtaining perfectly accurate keratometry and/or refraction measurements through pupils as narrow as 2.0 mm....

Medicine Products:

McDonald forceps for Silicone lens Serdarevic Inserter Fine Universal II Inserter KR-8000 Autokerato-refractometer